The differences in the pharmacokinetic (PK) characteristics of inhaled corticosteroids (ICSs) critically influence the profile of each of them, but also the significant differences in glucocorticoid receptor selectivity, potency, and physicochemical properties are critical in defining the pharmacodynamic (PD) profile of an ICS. The PK and PD properties of ICSs used in asthma and the importance of their interrelationship have been reviewed. The differences among the ICSs in PK and PD must be considered when an ICS should be prescribed to an asthmatic patient because a better understanding of the PK/PD interrelationship of ICSs could be important to better fit with the between-patient variability and within-patient repeatability in the response to ICSs that often complicate the therapeutic approach to the asthmatic patient. The role of the device in influencing the PK profile of an ICS must be always considered because it is crucial. Also patient-related factors and disease severity affect pulmonary deposition of ICS.

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment / Matera, M. G.; Rinaldi, B.; Calzetta, L.; Rogliani, P.; Cazzola, M.. - In: PULMONARY PHARMACOLOGY & THERAPEUTICS. - ISSN 1094-5539. - 58:(2019). [10.1016/j.pupt.2019.101828]

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment

Rinaldi B.;Calzetta L.;
2019-01-01

Abstract

The differences in the pharmacokinetic (PK) characteristics of inhaled corticosteroids (ICSs) critically influence the profile of each of them, but also the significant differences in glucocorticoid receptor selectivity, potency, and physicochemical properties are critical in defining the pharmacodynamic (PD) profile of an ICS. The PK and PD properties of ICSs used in asthma and the importance of their interrelationship have been reviewed. The differences among the ICSs in PK and PD must be considered when an ICS should be prescribed to an asthmatic patient because a better understanding of the PK/PD interrelationship of ICSs could be important to better fit with the between-patient variability and within-patient repeatability in the response to ICSs that often complicate the therapeutic approach to the asthmatic patient. The role of the device in influencing the PK profile of an ICS must be always considered because it is crucial. Also patient-related factors and disease severity affect pulmonary deposition of ICS.
2019
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment / Matera, M. G.; Rinaldi, B.; Calzetta, L.; Rogliani, P.; Cazzola, M.. - In: PULMONARY PHARMACOLOGY & THERAPEUTICS. - ISSN 1094-5539. - 58:(2019). [10.1016/j.pupt.2019.101828]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2910204
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 14
social impact